The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study

Not yet recruitingOBSERVATIONAL
Enrollment

118

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

October 10, 2026

Study Completion Date

October 10, 2027

Conditions
CarcinomaHepatocellular Carcinoma
Interventions
PROCEDURE

E-TACE

The 70/100μm drug-loaded microspheres were loaded with anthracyclines (30mg-50mg Idarubicin) at 2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded anthracyclines (30mg-50mg Idarubicin) with 2mL/3mLto embolize the tumor supplying arteries at different grades and diameters.

DRUG

Donafenib

400mg QD

Trial Locations (10)

Unknown

People's Hospital of Kaiyang County, Guiyang

The Second Affiliated Hospital of Hainan Medical Universsity, Haikou

Huai He Hospital of Henan University, Kaifeng

Luo He Central Hospital, Luohe

Luo Yang Central Hospital, Luoyang

Deng zhou People's Hospital, Nanyang

First People's Hospital of Shangqiu, Shangqiu

Zhou Kou Central Hospital, Zhoukou

Jiangxi Provincial People's Hospitail, Nanchang

Second People's Hospital of Jiaozuo, Jiaozuo

All Listed Sponsors
lead

Xuhua Duan

OTHER

NCT07180459 - The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study | Biotech Hunter | Biotech Hunter